VERICEL CORPORATION (VCEL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $45.31, VERICEL CORPORATION (VCEL) is priced for today's economics sustained for ~24.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/VCEL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Solve inputs: computed at a 12.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.1 years.

Reconcile: at the x-ray's 9.3% required return this reads ~16.7 years; the models below use their own rates.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=16)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Cartilage repair is essentially the whole business: the products already earn a 74.4% gross margin, and the price is paying about nine times revenue for a company that has not yet turned that gross margin into an operating profit.
• The demand is elective and heavily back-loaded, with fourth-quarter volumes averaging 34% of the annual MACI total over the five years through 2025, so a single soft surgical season shows up immediately.
• Second-quarter results arrive on July 30, 2026, the first look at whether the 30% revenue growth reported for the March quarter is holding.

Bull Case

Start with how this company pays for itself, because for a cell therapy business it is genuinely unusual. Borrowings are essentially absent from the capital structure. The March 2026 balance sheet carried 109.3 million dollars of cash and equivalents, 36.0 million dollars of short-term investments and 65.3 million dollars of longer-dated ones, and the quarter's operations contributed 16.4 million dollars rather than consuming anything. Companies that grow living cells for a living normally fund themselves by selling shares to strangers every eighteen months. This one is paying for its own expansion out of the products it already sells.

What it sells earns a 74.4% gross margin, which is the economic fact everything else rests on. MACI is an autologous implant: the surgeon takes a biopsy, the company grows the patient's own cartilage cells onto a membrane, and the implant goes back into the same knee. That process is the moat, because it is a manufacturing and logistics capability rather than a molecule, and it is why the company can widen the market without inventing a new product. The arthroscopic version is the clearest example. The filing describes it plainly: "MACI Arthro provides a less invasive technique compared to the open arthrotomy approach", used for defects up to 4 square centimetres. A less invasive delivery method converts surgeons who would not have offered the open procedure at all.

The same manufacturing base is being pointed at a second joint. Following an application to the FDA, the company "received Investigational New Drug ("IND") clearance for MACI's use in the ankle during the second quarter of 2025", and initiated the ankle study in the fourth quarter of that year. Nothing about that requires a new factory, a new cell line, or a new sales force. It requires a label.

Then there is the piece of the business nobody models. On March 31, 2026 the company entered a ten-year agreement with the U.S. Biomedical Advanced Research and Development Authority, the federal body that stockpiles medical countermeasures, covering NexoBrid, its enzymatic burn treatment. Government preparedness demand is not correlated with elective orthopaedic surgery volumes, which means it does something for the revenue profile that a second knee product could not.

All of which sets up the actual question: whether a 74.4% gross margin turns into an operating margin near 30%. In this cohort, that outcome demonstrably exists. KRYS converts 42.8% of revenue into operating profit on $417.3 million of revenue growing 25.1%. HALO converts 33.9% on $1.508 billion growing 39.1%. Those are trailing figures from their own filings, not projections. The honest counterexample sits in the same group: FOLD carries $634.2 million of revenue and converts 5.2%. The difference between the two outcomes is not the science. It is whether the selling organisation eventually stops growing as fast as the revenue does.

Bear Case

Elective knee surgery has a season, and the numbers on it are the company's own. Over the five years through 2025, first-quarter MACI volumes averaged 21% of the annual total while fourth-quarter volumes averaged 34%. That pattern exists because a cartilage repair is a scheduled procedure that patients time around deductibles and their own calendars, which is a polite way of saying the demand is deferrable. Deferrable demand is the first thing to go when household budgets tighten or when a hospital reprioritises its operating rooms, and a business at this valuation has no room in it for a slow surgical year.

The path from the factory to the patient is narrow at both ends. The company distributes MACI through two specialty pharmacies, Orsini and AllCare, and payment approval is not a back-office step but a gate: the filing states that "coverage level by the patient's private insurance plan, hospital or government payer is a prerequisite to the shipment of a MACI implant to a patient". No coverage, no shipment. On the other product, the dependency runs the other way. NexoBrid is made by MediWound under exclusive license and supply agreements "on a unit price basis, which may be increased pursuant to the terms of the agreements". One product cannot ship without a payer's consent; the other cannot ship without a supplier's, at a price that supplier can raise.

Now the economics as they actually stand rather than as they are meant to become. The trailing operating margin is minus 7.7%. Free cash flow of about $47.5 million looks respectable until stock-based compensation of roughly 40 million dollars over the same stretch is set beside it. Net of that charge, what the business generates for its owners is close to nothing. The share count has risen about 2% a year over the four years to March 2026, so the pile grows on one side of the ledger while ownership of it dilutes on the other, at broadly similar speed.

Which brings the argument to what the price actually requires. At about nine times revenue, it asks for an eventual operating margin near 29.8% and for revenue to grow at the fastest rate the business can fund from its own resources for something like twelve years. Only about 14% of comparably fast growers held that pace for even ten. The requirement is also unusually sensitive to something nobody at this company controls. Add a single percentage point to the cost of capital and the arithmetic shifts by more than two years. That makes it partly a bet on interest rates dressed as a bet on cartilage.

The methods are unanimous, which is rare and worth noticing. Every family lands below today's price, including the forward-growth ones that credit the revenue trajectory in full. The price stands roughly 414% above the earnings-power approaches and about 180% above the peer-multiple approaches. When no standard frame reaches, the price is not being defended by valuation at all. It is being defended by an expectation about the next decade.

Valuation

There is no profit to divide the price into, which changes what the exercise can be. Trailing operating profit is negative, so today's price has to be read against sales, and on that basis it runs at about nine times revenue. Two demands are folded into that multiple. The first is that the operating margin eventually reaches something near 29.8%. The second is that revenue grows at the fastest rate the business can fund out of its own cash flow for roughly twelve years.

The margin demand is not plucked from the air. It comes from taking the 74.4% gross margin the products already earn and applying an ordinary rate of conversion from gross profit down to operating profit. Read that way, the price is not asking for a better product or a higher selling price. It is asking for the same product, sold through a commercial organisation that eventually stops growing as fast as the revenue it produces. The trailing operating margin today is minus 7.7%, so the entire distance is in operating leverage that has not arrived yet.

No family of method reaches the current price. The asset-based approaches sit furthest away, which is unsurprising for a company whose value lives in a manufacturing process and a surgeon network rather than in anything on the balance sheet. More informative are the middle two: the price stands roughly 414% above the earnings-power approaches and about 180% above the peer-multiple approaches. Even the forward-growth approaches, which extend the recent revenue trajectory and credit it fully, land beneath the price.

The cohort supplies the useful test of whether the margin demand is reasonable. Two of these companies already operate above it, with KRYS at a 42.8% operating margin on $417.3 million of revenue and HALO at 33.9% on $1.508 billion. Two others sit well below despite larger revenue bases, with FOLD at 5.2% on $634.2 million and AXSM negative on $708.2 million. Scale alone does not deliver the margin in this business, and revenue growth alone does not either; AXSM is growing revenue 63.9% while converting nothing.

The balance sheet removes one class of risk from the argument completely. There is essentially no funded debt, liquid holdings ran to $109.3 million of cash and equivalents plus $36.0 million of short-term investments as of March 31, 2026, and the March quarter generated $16.4 million from operations, of which $11.3 million was stock compensation added back as a non-cash charge. A revolving facility was opened alongside, with roughly 1.1 million dollars of issuance costs capitalised, which is a liquidity option rather than leverage. Solvency is not the question here. Duration is, and no balance sheet shortens twelve years.

Catalysts

The next print is days away. Second-quarter results are scheduled for July 30, 2026. The comparison it will be read against was set on May 7, 2026, when the company reported total revenue up 30% to $68.4 million with MACI revenue growth of 22% and raised full-year guidance. Given how back-loaded the volume year is, a second-quarter figure is a directional read rather than a verdict, but guidance commentary alongside it is not.

The most consequential item this year has nothing to do with knees. On March 31, 2026 the company entered a ten-year agreement with the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response, covering NexoBrid. It was announced on April 2, 2026 as valued at up to $197 million for procurement and advanced development. A ten-year government procurement commitment behind a burn product is a different kind of revenue from an elective implant, and it is the sort of thing that changes a revenue multiple more than a quarter does.

Two regulatory threads run behind the numbers. The ankle indication moved from IND clearance in the second quarter of 2025 to an initiated patient study in the fourth quarter, and the company also has a United Kingdom approval pathway open for MACI. On the sell side, Truist raised its target to $54 from $42 with a Buy rating in mid-July 2026. That figure sits above where every family of method in this framework lands, which is consistent rather than contradictory: it credits the ankle indication, the arthroscopic expansion and the government agreement, none of which appear in a trailing number yet.

Peer Cohorts (Per Segment, With Filing Citations)

Cellular therapies & specialty biologics (reported)

• KRYS (Krystal Biotech, Inc.)
• FY2025 10-K: …competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be…
• FY2025 10-K: …biologic products. Investigational new drug, or IND, applications to the FDA are required before conducting human clinical testing of biologic products. Additionally, each clinical trial protocol for a gene therapy product candidate is reviewed by the FDA, and in limited instances the National Institutes of Health…
• FOLD (AMICUS THERAPEUTICS, INC.)
• FY2025 10-K: …including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with both existing and new therapies that may become available in the future. Many of our competitors may have…
• FY2025 10-K: …attract, retain and motivate qualified personnel. • We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. • Our employees, independent contractors, principal investigators,…
• APLS (APELLIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …including: • the efficacy and safety of the product; • the potential advantages of the product compared to competitive therapies; 50 Table of Contents • the prevalence and severity of any side effects; • the clinical indications for which the product is approved; • whether the product is designated under physician…
• FY2025 10-K: , Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and…
• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: …multiple myeloma who are ineligible for autologous stem cell transplant. In December 2019, Janssen elected epidermal growth factor receptor and mesenchymal-epithelial transition factor as a bispecific antibody (amivantamab) target on an exclusive basis, which is being studied in solid tumors. In September 2022,…
• FY2025 10-K: …of drugs and biologics by reducing the injection volume for the same dosage and expanding opportunities for at-home and health care provider administration. The Surf Bio hyperconcentration technology is being developed to create high antibody and biologic concentrations of up to 500 mg/mL, for delivery in a single…
• IONS (IONIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …know-how to develop and maintain a competitive position in RNA-targeted therapeutics generally and to protect our investment in specific products. To this end, we focus our resources on intellectual property, or IP, that drives value for our company. Product-Specific IP Each of our medicines is protected worldwide by…
• FY2025 10-K: Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 76 Item 13. Certain Relationships and Related Transactions, and Director Independence 77 Item 14. Principal Accountant Fees and Services 77 PART IV Item 15. Exhibits and Financial Statement Schedules 77 Signatures…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …competition with respect to our current products and product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. There are…
• FY2025 10-K: …the United States to commercialize our products and will further expand that team as we plan for anticipated drug approvals of our product candidates. We believe that we have cost-effectively implemented a targeted sales force required to commercialize our products. Support for this team includes sales management,…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: , materially, and permanently impact our revenues, profitability, and cash flows from those products and may substantially limit our ability to obtain a return on the investments we have made in our products. If our competitors develop or market alternatives for the treatment of our target indications, our commercial…
• FY2025 10-K: …Zuranolone Products. Biogen has also agreed to pay us tiered royalties based on net sales of the Licensed Zuranolone Products in the Biogen Territory of high-teens to low-twenties percentages. If we have exercised our Opt-Out Right in the U.S. with respect to Licensed Zuranolone Products, Biogen has agreed to pay us…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: …CBS105 for treatment-resistant narcolepsy and CBS104 for refractory epilepsy (together the "Candidates"), using cell replacement therapy for the treatment of refractory epilepsies and treatment-resistant narcolepsy. In August 2021, we acquired HBS-102, a Melanin-concentrating hormone receptor type 1 (MCHR1)…
• FY2025 10-K: …are several companies pursuing clinical development of therapies including, but not limited to, product candidates from Avidity Biosciences, Inc., Vertex Pharmaceuticals, Inc., Entrada Therapeutic, Inc. and PepGen, Inc. ​ DS and LGS. There are multiple FDA approved therapies for the treatment of DS, LGS or both DS…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.